FDA Should Drop Ban On Office Compounding, US House Members Say
Executive Summary
Commissioner Gottlieb stands pat (actually he was sitting) during hearing where lawmakers suggest FDA has gone overboard in implementing DQSA. And while he acknowledges that '503 lite' isn't the best term to use, Gottlieb says agency’s plan to create different risk tiers for drug outsourcing pharmacies offers the flexibility that can entice more traditional pharmacies to register as outsourcing centers, and thus be subject to GMP oversight.
You may also be interested in...
FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan
FDA wants more companies to adopt continuous manufacturing, which could expand the US manufacturing base.
FDA Commissioner Outlines Priorities For Tightening Oversight Of Drug Compounding Facilities
To encourage drug compounding pharmacies to register as 503B drug outsourcing facilities, FDA plans to propose assigning these pharmacies a lower risk category, thus subjecting them to less stringent GMP controls if they make limited volumes of drugs as part of a “2018 Compounding Policy Priorities Plan” announced by FDA Commissioner Scott Gottlieb.
FDA Works To Encourage Office-Use Compounding In Advance Of Legislation
FDA looks to carve out a place for office-use compounding within Section 503B, the new framework created after deadly fungal contamination of products, while industry supports efforts in Congress to allow it under the traditional Section 503A.